Do PPIs Like Omeprazole Deplete Vitamin B12 and Magnesium? What the Evidence Shows for Long-Term Users in India (2026)

Proton pump inhibitors (PPIs) like omeprazole are associated with measurable depletion of both vitamin B12 and magnesium in long-term users. A 2022 cohort study of 1,225 patients found that more than half of male PPI users had low B12 levels, and a meta-analysis of 131,507 patients confirmed that PPI use raises the odds of hypomagnesemia by 71% after adjustment for confounders. For the tens of millions of Indians who take omeprazole, pantoprazole, or rabeprazole daily — often without a formal re-evaluation of whether they still need the drug — these numbers are not abstract.

The table below summarises the key evidence on the two most clinically significant nutrient deficiencies linked to PPI use.

Nutrient	Mechanism of depletion	Risk magnitude	Typical onset	Key population at risk
Vitamin B12	Reduced gastric acid impairs release of B12 from food proteins; intrinsic factor activity also suppressed	OR ~1.5–2× in long-term users; >55% of male users in one cohort had low levels	Gradual over several years; clinical symptoms may lag further	Men aged 18–40, vegetarians/vegans, elderly, those on metformin concurrently
Magnesium	PPIs reduce activity of intestinal TRPM6/TRPM7 transport proteins, lowering active Mg absorption	Pooled adjusted OR 1.71 (95% CI 1.33–2.19); high-dose users OR 2.13	Most cases after ≥1 year; documented as early as 3 months	Patients on diuretics, digoxin, or insulin; those with poor dietary Mg intake
Vitamin C	Reduced gastric acid lowers ascorbic acid concentration in gastric juice	Modest reduction; less studied	Unclear	Malnourished patients
Calcium / Iron	Acid needed for solubilisation and absorption of non-haem iron and calcium salts	Modest increase in fracture risk with long-term use	Years of use	Post-menopausal women, elderly, those on low-calcium diets

How do PPIs actually work, and why does that affect nutrients?

A proton pump inhibitor irreversibly blocks the hydrogen-potassium ATPase enzyme system (the "proton pump") on the surface of gastric parietal cells, suppressing the final step of acid production regardless of the stimulus. This is what makes PPIs more effective than H2-receptor antagonists for conditions like gastro-oesophageal reflux disease (GERD), erosive oesophagitis, and peptic ulcer disease.

The same acid suppression that heals oesophageal tissue changes the gastric environment in ways that affect nutrient chemistry. As physician Dr Kunal Sood explained in a September 2026 post, "Reduced acidity can also change how certain nutrients are absorbed." The stomach is not just a digestion chamber — it is a biochemical processing unit whose acidic pH is essential for liberating minerals from food matrices and activating enzymes that cleave vitamins from carrier proteins.

A 2013 review published in Therapeutic Advances in Drug Safety by Joel Heidelbaugh of the University of Michigan found that PPIs have been associated with an increased risk of deficiencies impacting vitamin B12, vitamin C, calcium, iron, and magnesium metabolism. The review noted that while risks are considered relatively low in the general population, they become clinically notable in elderly and malnourished patients — two groups disproportionately represented among India's chronic PPI users.

Why does long-term PPI use deplete vitamin B12?

Vitamin B12 absorption is a multi-step process that begins in the stomach: dietary B12 must first be released from food proteins by hydrochloric acid and pepsin, then bound to intrinsic factor (a glycoprotein secreted by parietal cells), and finally absorbed in the terminal ileum. PPIs disrupt the very first step.

Dr Sood's explanation is precise: "B12 from food must first be released from proteins with the help of stomach acid and digestive enzymes. Long-term acid suppression can make this step less efficient, and deficiency may gradually develop over several years." B12 from supplements or fortified foods — where the vitamin is already in free form — is less affected, which is why supplementation is often effective as a corrective strategy.

The 2022 cohort study conducted at KRL Hospital in Islamabad, which enrolled 1,225 patients on PPI therapy for more than one year, found that vitamin B12 levels were significantly lower in omeprazole users than in pantoprazole users — a finding that matters for Indian patients, since omeprazole remains the most commonly prescribed PPI in the country due to its low cost and wide availability. A vitamin B12 deficiency was 0.5 times more likely in patients taking PPIs overall, and the risk was concentrated in men aged 18 to 40. This is a counterintuitive finding — younger men are not typically considered a high-risk group for B12 deficiency — and it underscores the importance of monitoring even in patients who appear otherwise healthy.

The same study also noted that some earlier research found no significant B12 differences in patients on PPIs for over four years when routine monitoring was in place — suggesting that the deficiency is preventable with appropriate surveillance, not inevitable.

What does B12 deficiency actually feel like?

The clinical picture of B12 deficiency is one that Indian primary care physicians may underdiagnose because its symptoms overlap with anaemia from other causes, diabetic neuropathy, and general fatigue. Dr Sood outlined the key presentations: B12 deficiency can impair red blood cell production, causing fatigue, weakness, breathlessness, or palpitations, and can also affect nerves, causing numbness or tingling in the hands and feet.

One point he emphasised deserves particular attention: "Neurological symptoms can occur without anaemia." A normal complete blood count does not rule out B12 deficiency. Subacute combined degeneration of the spinal cord — a rare but serious neurological complication of severe B12 deficiency — can develop insidiously in patients whose haemoglobin appears normal. For Indian patients who are also vegetarian or vegan (a large proportion of the population), baseline B12 levels may already be suboptimal before PPI therapy begins, compressing the timeline to clinical deficiency.

The Heidelbaugh review also noted that the risk is amplified in patients on concurrent metformin therapy — a drug widely prescribed for type 2 diabetes in India — since metformin independently reduces B12 absorption through a different mechanism involving calcium-dependent ileal membrane transport.

Why does long-term PPI use deplete magnesium?

PPI-associated hypomagnesemia is a clinically significant reduction in serum magnesium concentration caused by impaired intestinal magnesium absorption. The mechanism is distinct from the B12 pathway and involves the gut's active transport system rather than gastric acid chemistry.

Intestinal magnesium absorption occurs through two routes: passive paracellular diffusion (which depends on luminal concentration) and active transcellular transport mediated by TRPM6 and TRPM7 proteins on the apical membrane of enterocytes. Research cited in the 2019 meta-analysis shows that TRPM activity is regulated by intraluminal pH — an acidic environment increases TRPM6 activity. When PPIs raise luminal pH, TRPM6 activity falls, reducing active magnesium uptake. The result is hypomagnesemia combined with decreased urinary magnesium excretion as the kidneys attempt to compensate.

Dr Sood noted that "most reported cases occur after a year or more, although it has been documented after at least three months." That three-month threshold matters for clinicians who assume short courses of PPIs are entirely risk-free with respect to electrolytes.

What does the meta-analysis data actually show?

The 2019 meta-analysis by Srinutta and colleagues, which pooled data from 16 observational studies covering 131,507 patients, is the most comprehensive dataset available on this question. Among PPI users, 19.4% had hypomagnesemia compared to 13.5% among non-users — a difference of nearly 6 percentage points in absolute terms. The pooled adjusted odds ratio was 1.71 (95% CI 1.33–2.19, P < 0.001), confirming a statistically solid association even after adjustment for confounders.

The meta-analysis also found a dose-response relationship: high-dose PPI use was associated with higher odds of hypomagnesemia relative to low-dose use, with a pooled adjusted OR of 2.13 (95% CI 1.26–3.59, P = 0.005). This pattern strengthens the causal inference — it is not merely that sicker patients who need higher PPI doses also happen to have lower magnesium, but that the drug itself appears to drive the depletion in a dose-dependent manner.

The FDA recognised this risk in 2011, issuing a drug safety communication stating that low magnesium levels could be associated with long-term PPI use. That communication was based on a review of 38 adverse event reports and 23 published case reports, and it resulted in hypomagnesemia warnings being added to the labelling of all PPIs. The meta-analysis authors note that the FDA's original decision was not based on large observational studies — the subsequent evidence has now substantially reinforced that warning.

What are the symptoms of low magnesium from PPIs?

Hypomagnesemia from PPIs can present with muscle cramps, tremors, tetany, cardiac arrhythmias, and seizures in severe cases. Mild hypomagnesemia is often asymptomatic, which is why it goes undetected without routine monitoring. For Indian patients who are also on diuretics (commonly prescribed for hypertension), the risk compounds — diuretics increase urinary magnesium excretion while PPIs reduce intestinal absorption, creating a double-depletion scenario.

One clinically important feature of PPI-induced hypomagnesemia is that it typically does not respond to magnesium supplementation alone as long as the PPI is continued, because the absorption defect persists. Resolution usually requires either discontinuing the PPI or switching to an H2-receptor antagonist. This distinguishes PPI-induced hypomagnesemia from dietary magnesium deficiency, where supplementation is straightforwardly effective.

Are some PPIs worse than others for nutrient depletion?

The KRL Hospital cohort study found that vitamin B12 levels were significantly lower in omeprazole users than in pantoprazole users. This is a clinically relevant distinction for Indian prescribers, since both drugs are widely available as generics and are often considered interchangeable for acid suppression. The study did not establish a definitive mechanistic explanation for the difference, but potency of acid suppression and pharmacokinetic differences between the two molecules are plausible contributors.

The Heidelbaugh review noted that the class as a whole — including omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, and dexlansoprazole — carries the same general risk profile for nutrient depletion, since all work through the same proton pump mechanism. The magnitude of risk may vary by molecule and dose, but no PPI is categorically safe from a nutrient-depletion standpoint when used long-term.

For Indian patients, switching from omeprazole to pantoprazole may offer a modest B12 advantage, but it does not eliminate the need for monitoring. Rabeprazole, also commonly prescribed in India, has not been studied as extensively in this specific context.

Who is at highest risk among Indian long-term PPI users?

Several factors converge to make certain Indian patient populations particularly vulnerable to PPI-induced nutrient deficiencies.

Vegetarians and vegans make up an estimated 20% to 40% of India's population depending on the survey — one of the highest proportions in the world. Dietary B12 is found almost exclusively in animal products, meaning vegetarian PPI users may start with borderline B12 levels before the drug further impairs absorption. The combination can accelerate the timeline to clinical deficiency significantly.

Concurrent metformin users face a dual depletion mechanism for B12. Type 2 diabetes affects an estimated 77 million Indians, and metformin is the first-line oral agent. It independently reduces B12 absorption by interfering with calcium-dependent ileal membrane transport — a separate pathway from the one PPIs affect.

Elderly patients are specifically flagged in the Heidelbaugh review as a group where PPI-associated nutrient risks become clinically notable. Gastric atrophy — which reduces intrinsic factor production — is more common in older adults, compounding the PPI effect on B12 absorption.

Patients on diuretics face heightened magnesium risk. Diuretics increase urinary magnesium losses; combined with PPI-mediated reduction in intestinal magnesium absorption, this creates a high-risk scenario for hypomagnesemia.

Patients on long-term PPIs without re-evaluation represent perhaps the largest at-risk group. The Heidelbaugh review identified PPI overutilisation as a systemic problem — "the majority of patients who receive PPIs do so for at least one year without a clear indication." In India, where PPIs are available over the counter and are frequently self-prescribed for chronic acidity, this pattern is likely amplified.

Should Indian patients on long-term PPIs be routinely screened?

The Heidelbaugh review stated that "no current evidence recommends routine screening or supplementation for these potential vitamin and mineral deficiencies in patients on either short- or long-term PPI therapy." That guidance, however, dates to 2013 and predates the larger observational datasets now available. The clinical consensus has shifted toward targeted monitoring in high-risk groups, even if universal screening remains debated.

A reasonable approach for Indian clinicians managing patients on PPIs for more than one year would include:

Serum B12 measurement at baseline and annually in vegetarians, vegans, elderly patients, and those on concurrent metformin
Serum magnesium measurement in patients on diuretics, digoxin, or insulin, and in those with symptoms of neuromuscular irritability
Periodic re-evaluation of whether PPI therapy is still indicated — the Heidelbaugh review noted that failure to re-evaluate the need for continuation is the primary driver of PPI overutilisation

The KRL Hospital study found that when routine monitoring was in place, even four-plus years of omeprazole or pantoprazole did not necessarily result in B12 deficiency — suggesting that the deficiency is a preventable complication, not an inevitable consequence of PPI use.

What can long-term PPI users do to protect their nutrient status?

For patients who genuinely need long-term PPI therapy — those with Barrett's oesophagus, severe erosive oesophagitis, or Zollinger-Ellison syndrome — the goal is not to stop the drug but to mitigate nutrient losses. Several practical strategies are supported by the evidence.

B12 supplementation: PPI-induced B12 malabsorption primarily affects food-bound B12, which requires acid for liberation. Supplemental cyanocobalamin or methylcobalamin in free form bypasses the gastric step and is absorbed normally. High-dose oral B12 (1,000 mcg daily) or intramuscular injections are both effective. Indian patients who are already vegetarian should consider supplementation proactively rather than waiting for deficiency to develop.

Dietary magnesium optimisation: While supplemental magnesium absorption is also partially impaired by PPIs (since the TRPM6 defect affects all luminal magnesium), dietary sources with high magnesium density — nuts, seeds, legumes, dark leafy greens — may help maintain marginal adequacy. PPI-induced hypomagnesemia often does not fully resolve with supplementation alone, however.

Step-down therapy: For patients whose acid symptoms are controlled, stepping down from a PPI to an H2-receptor antagonist (like famotidine or ranitidine where available) removes the TRPM6-mediated magnesium absorption defect while still providing meaningful acid suppression. This is particularly relevant for patients whose primary concern is magnesium depletion.

On-demand dosing: For patients with non-erosive GERD or functional dyspepsia, taking the drug only when symptoms occur rather than continuously substantially reduces cumulative acid suppression and likely reduces nutrient depletion risk, though direct evidence on this specific question is limited.

If you are managing other aspects of nutritional health alongside PPI therapy, our articles on berberine for insulin resistance and best blood pressure supplements in India may be relevant, particularly for patients with overlapping metabolic conditions where multiple drugs interact with nutrient status.

What is the broader context of PPI overuse in India?

PPIs are among the most prescribed drugs globally, and India is no exception. Omeprazole and pantoprazole are available over the counter at pharmacies across the country, and the festive season — with its heavy, spice-rich meals — predictably drives a spike in self-medication for acidity and heartburn. The Hindustan Times report noted this seasonal pattern explicitly, with Dr Sood cautioning that "prolonged acid suppression can contribute to vitamin B12 deficiency and low magnesium in some people, which is why new symptoms deserve attention."

The Heidelbaugh review estimated that approximately 80% of PPIs in the US are purchased without a prescription or physician evaluation — a figure that likely underestimates the self-medication rate in India, where pharmacy access is easier and prescription requirements are less consistently enforced. The financial scale is also significant: US PPI sales alone reached approximately $9.7 billion in 2010, with generic omeprazole and pantoprazole ranking in the top five generic prescriptions by expenditure.

PPIs are not dangerous drugs that should be avoided — they are highly effective for their indicated uses and have a genuinely favourable safety profile for short-term use. The issue is duration and monitoring. A two-week course of omeprazole for an acute peptic ulcer carries essentially no meaningful risk of B12 or magnesium depletion. A two-year course taken without re-evaluation or monitoring carries a real and quantifiable risk, particularly in the high-risk groups described above.

As the Heidelbaugh review concluded: "Reducing inappropriate prescribing of PPIs can minimize the potential risk of vitamin and mineral deficiencies." For Indian patients and clinicians alike, that sentence is the practical bottom line.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your medication or supplementation regimen.